All In Biotech

Drug Trial Radar · NCT05352672

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,546 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,546

Actual

Start

Jul 14, 2022

Primary completion

Mar 12, 2026

Study completion Sep 16, 2031

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Apr 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on patients with a type of skin cancer known as melanoma. The aims of the study are to see how effective the combination of fianlimab and cemiplimab are in treating the melanoma skin cancer, in comparison with a medication, pembrolizumab, approved for the treatment of melanoma skin cancer in adults, and to observe any similarities, or differences, in how the study drugs work in adolescent participants compared with adult participants. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections. * How administering the study drugs might improve quality of life

Conditions

  • Melanoma

Interventions

  • FianlimabDrug

    Intravenous (IV) infusion

  • CemiplimabDrug

    IV infusion

  • PembrolizumabDrug

    IV infusion

  • PlaceboDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Approximately 27 months

Locations

210 sites in 24 countries. Site status is shown where the registry gives one.

  • UC San Diego

    La Jolla, California

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • Orlando Health

    Orlando, Florida

  • Seidman Cancer Center

    Cleveland, Ohio

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • Centro de Investigaciones Medicas y Desarrollo LC S.R.L. (LC Investigacion)

    Buenos Aires, Argentina

  • Exelsus

    San Miguel de Tucumán, Argentina

  • DIABAID - Instituto de Asistencia Integral en Diabetes

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Centro Medico Austral

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Centro de Investigacion Pergamino

    Pergamino, Buenos Aires, Argentina

  • Instituto de Oncologia de Rosario

    Rosario, Santa Fe Province, Argentina

  • Gold Coast Hospital and Health Service

    Southport, Queensland, Australia

  • Townsville University Hospital

    Townsville, Queensland, Australia

  • Calvary North Adelaide Hospital

    North Adelaide, South Australia, Australia

  • Icon Cancer Centre Hobart

    Hobart, Tasmania, Australia

  • Andrew Love Cancer Centre

    Geelong, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • Medical University Vienna

    Vienna, Austria

  • University Hospital Saint Poelten

    Sankt Pölten, Lower Austria, Austria

  • Medical University of Graz

    Graz, Styria, Austria

  • Medical University Innsbruck

    Innsbruck, Tyrol, Austria

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Centre Hospitalier Universitaire Universite Catholique de Louvain Namur Site Sainte Elisabeth

    Namur, Belgium

  • AZ Groeninge

    Kortrijk, West-Vlaanderen, Belgium

  • AZ Nikolaas

    Sint-Niklaas, West-Vlaanderen, Belgium

  • Oncosite Centro De Pesquisa Em Oncologia

    Ijuí, Brazil

  • INCA - Brazilian National Cancer Institute

    Rio de Janeiro, Brazil

  • Instituto COI

    Rio de Janeiro, Brazil

  • Hemomed

    São Paulo, Brazil

  • Hospital Sirio Libanes

    São Paulo, Brazil

  • Sao Camilo Oncologia

    São Paulo, Brazil

  • Hospital Sao Rafael

    Salvador, Estado de Bahia, Brazil

  • Hospital das Clinicas da Universidade Federal de Minas Gerais

    Belo Horizonte, Minas Gerais, Brazil

  • Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil

  • Hospital Bruno Born

    Lajeado, Rio Grande do Sul, Brazil

  • Instituto do Cancer em Hospital Sao Vicente de Paulo

    Passo Fundo, Rio Grande do Sul, Brazil

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Moinhos de vento

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro de Pesquisa em Oncologia PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fundacao Pio XII - Hospital de Amor Amazonia

    Porto Velho, Rondônia, Brazil

Showing 40 of 210 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.